Harshabad Singh

1.5k total citations
43 papers, 755 citations indexed

About

Harshabad Singh is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Harshabad Singh has authored 43 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Harshabad Singh's work include Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (6 papers). Harshabad Singh is often cited by papers focused on Pancreatic and Hepatic Oncology Research (10 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (6 papers). Harshabad Singh collaborates with scholars based in United States, India and Denmark. Harshabad Singh's co-authors include Bruce A. Chabner, Dan L. Longo, B.R. Sharma, Dasari Harish, Anup Sharma, Eyal C. Attar, D. Gary Gilliland, Zuzana Tóthová, Scott A. Armstrong and Kristina Brumme and has published in prestigious journals such as Nature, Cell and Journal of Clinical Oncology.

In The Last Decade

Harshabad Singh

36 papers receiving 742 citations

Peers

Harshabad Singh

ONCOL

SURGE

John T. Cole United States

Cheryl L. Hardy United States

Timothy Chevassut United Kingdom

Aurora Medina‐Sansón Mexico

Fábio Pires de Souza Santos Brazil

Cassandra Smith United States

İsmail Okan Türkiye

Cai‐Wen Duan China

Rafał Watrowski Germany

Mariana Silva Portugal

John T. Cole United States

Harshabad Singh

110 ×0.3

189 ×1.0

ONCOL

71 ×0.6

SURGE

86 ×0.8

58 ×0.6

Citations per year, relative to Harshabad Singh Harshabad Singh (= 1×) peers John T. Cole

Countries citing papers authored by Harshabad Singh

Since Specialization

Citations

This map shows the geographic impact of Harshabad Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harshabad Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harshabad Singh more than expected).

Fields of papers citing papers by Harshabad Singh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harshabad Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harshabad Singh. The network helps show where Harshabad Singh may publish in the future.

Co-authorship network of co-authors of Harshabad Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Harshabad Singh. A scholar is included among the top collaborators of Harshabad Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harshabad Singh. Harshabad Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sweeney, Kieran, Paul Johannet, Oliver Artz, et al.. (2025). 111O The mechanism of mismatch repair deficiency (MMRd) informs survival outcomes derived from immune checkpoint blockade (ICB) across MMRd solid tumors. Annals of Oncology. 36. S237–S238.

Ardalan, Bach, Yasmine Baca, Andrew Hinton, et al.. (2025). Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Clinical Cancer Research. 31(6). 1082–1090. 5 indexed citations

Guo, Jimmy A., Kyle E. Evans, Kazuki Takahashi, et al.. (2025). Integrative genomic identification of therapeutic targets for pancreatic cancer. Cell Reports. 44(9). 116191–116191.

Chewcharat, Api, et al.. (2025). Eculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report. American Journal of Kidney Diseases. 86(5). 710–714.

Singh, Harshabad, T. Lu, Zhixin Zhao, et al.. (2024). Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance.. Journal of Clinical Oncology. 42(3_suppl). 264–264.

Pandey, Aditya, et al.. (2024). Anti-KRAS G12C and Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer: A Case Report. JCO Precision Oncology. 8(8). e2400547–e2400547. 1 indexed citations

Singh, Harshabad, Lisa Bloudek, Ling‐I Hsu, et al.. (2023). Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer. JNCI Cancer Spectrum. 8(1). 9 indexed citations

Sahgal, Pranshu, Deepa T. Patil, Zsófia Sztupinszki, et al.. (2023). Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. iScience. 26(11). 108169–108169. 5 indexed citations

Singh, Harshabad, Jason L. Hornick, Shariq Madha, et al.. (2021). Hybrid Stomach-Intestinal Chromatin States Underlie Human Barrett’s Metaplasia. Gastroenterology. 161(3). 924–939.e11. 23 indexed citations

10.

Singh, Harshabad, Davide Seruggia, Shariq Madha, et al.. (2021). Transcription factor-mediated intestinal metaplasia and the role of a shadow enhancer. Genes & Development. 36(1-2). 38–52. 14 indexed citations

11.

Liang, Xiaoyan, Yaying Yang, Prajna Hebbar, et al.. (2021). An Enhancer-Driven Stem Cell–Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer. Gastroenterology. 162(1). 209–222. 45 indexed citations

12.

Rubinson, Douglas A., Brian M. Wolpin, Ilana S. Warsofsky, et al.. (2021). Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. Journal of Gastrointestinal Oncology. 12(6). 3133–3140. 4 indexed citations

13.

Singh, Harshabad, Yang Liu, Xiuli Xiao, et al.. (2016). Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget. 7(20). 29211–29215. 22 indexed citations

14.

Cheng, Xingxing S., et al.. (2014). The Root of This Evil: Microangiopathic Hemolytic Anemia and Renal Failure. The American Journal of Medicine. 128(1). 21–23. 1 indexed citations

15.

Sykes, Stephen M., Steven Lane, Lars Bullinger, et al.. (2011). AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias. Cell. 146(5). 697–708. 217 indexed citations

16.

Singh, Harshabad, Lillian Werner, Daniel J. DeAngelo, et al.. (2011). Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD. American Journal of Hematology. 86(7). 625–627. 7 indexed citations

17.

Singh, Harshabad, Lillian Werner, Daniel J. DeAngelo, et al.. (2011). Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leukemia Research. 35(12). 1611–1615. 7 indexed citations

18.

Sykes, Stephen M., Steven Lane, Lars Bullinger, et al.. (2011). AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias. Cell. 147(1). 247–247. 2 indexed citations

19.

Sharma, B.R., et al.. (2008). Injuries to neck structures in deaths due to constriction of neck, with a special reference to hanging. Journal of Forensic and Legal Medicine. 15(5). 298–305. 75 indexed citations

20.

Sharma, B.R. & Harshabad Singh. (2006). Role of forensic medicine in mass casualty incident. Journal of Punjab Academy of Forensic Medicine & Toxicology. 6(6). 25–30.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact